3378 — Hanx Biopharmaceuticals (Wuhan) Co Income Statement
0.000.00%
Last trade - 00:00- HK$2.32bn
- HK$2.48bn
Annual income statement for Hanx Biopharmaceuticals (Wuhan) Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 0 | 0 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Unusual Expense / Income | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 94.6 | 119 |
| Operating Profit | -94.6 | -119 |
| Total Net Non Operating Interest Income / Expense | ||
| Net Income Before Taxes | -93.4 | -123 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -85.2 | -117 |
| Minority Interest | ||
| Net Income Before Extraordinary Items | ||
| Net Income | -76.1 | -116 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -76.1 | -116 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.558 | -0.799 |